Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection

Phase II Study of Caspofungin Based Combined Anti-fungal Therapy for Patients With Proven or Probable Invasive Fungal Infection After Allogeneic Stem Cell Transplantation From HLA-matched Unrelated or HLA-mismatched Related Donors

In this prospective phase II observational study, we plan to assess the efficacy and tolerability of caspofungin based combined anti-fungal therapy for proven or probable IFI in a group of patients received allo-HSCT transplantation with high risk of IFI: HLA matched unrelated donor or mismatched donor conditioning with ATG containing regimen or present III-IV aGVHD or extensive GVHD undergoing high-dose steroid treatment.

Patients will recieve caspofungin with either voriconazole or amphotericin B as combination therapy for fungal infection

Inclusion Criteria:

• adult patient undergoing allogeneic hematopoietic stem cell transplantation
• age 18-55 years
• with inform consent
• no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage
• HLA mismatched related (3~5/6) or unrelated donors (at least 8/10)
• proven or probable IFI

Exclusion Criteria:

• age less than 18 years or over 56 years
• HLA mismatched related donor
• liver function/renal function damage (over 2 X upper normal range)
• with mental disease